BTS Group Invests in ZIM to Expand into Global eSIM Connectivity Solutions
8.4.2025 06:00:00 CEST | Business Wire | Press Release
BTS Group, a leading investor in global communications and technology, has announced a strategic investment inZIM Connections(ZIM), a gateway to global eSIM connectivity for businesses and consumers worldwide.
This investment establishes a collaboration between BTS, a leading global provider, technology enabler, and trusted partner to CommTech players owned by BTS Group, and ZIM, a frontrunner in global eSIM solutions. By leveraging the complementary strengths of both companies, this partnership will drive enhanced global connectivity solutions through eSIM technology for operators and end users.
“The global eSIM market is experiencing remarkable growth, with projections estimating an increase from $4.8 billion in 2023 to $34.6 billion by 2033*. With smartphone eSIM adoption expected to reach 76% by 2030**, this investment represents a strategic move into one of the fastest-growing segments in telecom,” said Rafael Olloqui, CEO and Co-Founder of BTS Group.“As global travel and eSIM adoption accelerate, we're helping operators capitalize on emerging roaming opportunities.”
Through this partnership, BTS will leverage its extensive relationships with mobile network operators (MNOs) to bring direct mobile connectivity to ZIM. This will improve end user experience by enabling faster, more reliable mobile access across regions, while also creating new revenue opportunities for mobile providers by driving global eSIM roaming traffic from global users and travelers to their networks.
“This move into eSIM is a key part of our broader strategy to support MNOs as they shift toward digital assets, particularly internationally,” noted Andrés Proaño, Chief Revenue Officer of BTS. “It complements other digital solutions we've introduced—such as Mobile ID and cloud-based services—by enabling operators to unlock new sources of value in an increasingly digital and mobile world.”
Additionally, BTS will offer a white-label eSIM app and platform, powered by ZIM, to its operator partners. This solution enables MNOs to rapidly launch a branded, customer-facing eSIM app connected to their existing backend infrastructure—without complex integration or in-house development—while maintaining ownership of the underlying connectivity and giving them full visibility and control over their users. Supporting coverage in 200+ global destinations, the app provides end users with a dashboard interface to manage their eSIMs, while allowing operators to maintain their brand presence and extend their reach to roamers or other customer segments.
“Joining forces with BTS allows us to scale our technology and reach, making seamless, high-quality mobile connectivity accessible to more users and businesses around the world,” emphasized Giulia Acchioni Mena, Co-Founder and COO of ZIM Connections. “With BTS as a strategic partner, we can bring our white-label eSIM solution to a broader range of operators—making it easy for them to deliver global coverage while eliminating the technical complexities traditionally associated with eSIM implementation.”
This collaboration combines BTS’ direct connections to MNOs and operational expertise with ZIM’s advanced eSIM platform and technology. Together, they enable operators to deliver seamless mobile connectivity with less complexity and greater efficiency—unlocking new opportunities in a rapidly evolving global market.
About BTS Group
BTS Group is a leading investment group driving innovation and growth in the global communications and technology sectors. Through its portfolio of companies, BTS Group enables advanced solutions in voice, cloud telephony, messaging, omnichannel, identity, eSIM connectivity, and digital transformation, serving operators, enterprises, and digital players worldwide. With a strategic vision focused on scalability, technological excellence, and long-term value creation, BTS Group fosters the development of next-generation communication solutions and accelerates industry-wide innovation.
About BTS
Owned by BTS Group, BTS is a leading global provider, technology enabler, and trusted partner to CommTech players. Leveraging its proprietary S1 Platform, an international network of 400+ partners, and 180+ direct links, BTS delivers advanced solutions across Global Connectivity, Smart Voice, Identity, Managed Communications, Omnichannel, Protection, and Analytics—driving growth for Operators, MNOs, CPaaS, and Hyperscalers. BTS powers 18+ billion voice minutes annually, enables the delivery of 500M+ messages worldwide, and provides extensive cloud numbers coverage in 90+ hard-to-reach markets, ensuring seamless and secure global communications.
About ZIM Connections
ZIM Connections is the Gateway to Global eSIM Connectivity for Businesses and Customers Worldwide. ZIM provides seamless international connectivity solutions that help businesses and individuals stay connected effortlessly. By offering a plug-and-play eSIM platform with global coverage in over 200 destinations, ZIM simplifies connectivity management and enables telecom providers to expand their services without complex integration.
* The Business Research Company
**GSMA Intelligence
View source version on businesswire.com: https://www.businesswire.com/news/home/20250407495454/en/
Contacts
For BTS
Paula Ruiz
pruiz@bts.io
+34 97 62 14 88 3
For ZIM Connections
Giulia Acchioni Mena
giulia.acchioni@zimconnections.com
zimconnections.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.zimconnect
ions.com%2F&esheet=54234875&newsitemid=20250407495454&lan=en-US&anchor=zimconnec
tions.com&index=6&md5=6a0ac49150185571c6a1591ac7163466
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom